🇺🇸 HMG-CoA Reductase Inhibitor in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Alopecia — 1 report (10%)
2. Atrial Fibrillation — 1 report (10%)
3. Basal Cell Carcinoma — 1 report (10%)
4. Blood Chloride Decreased — 1 report (10%)
5. Dehydration — 1 report (10%)
6. Dyspnoea — 1 report (10%)
7. Fluid Overload — 1 report (10%)
8. Gastroenteritis Viral — 1 report (10%)
9. Loss Of Consciousness — 1 report (10%)
10. Pitting Oedema — 1 report (10%)

Source database →

Frequently asked questions

Is HMG-CoA Reductase Inhibitor approved in United States?

HMG-CoA Reductase Inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for HMG-CoA Reductase Inhibitor in United States?

Seoul National University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.